Schedules of Controlled Substances: Placement of Ethylphenidate in Schedule I

The DEA’s placement of ethylphenidate in Schedule I reflects regulatory concern about a novel synthetic compound with stimulant properties and abuse potential, though clinical evidence on this specific agent remains sparse. Ethylphenidate, an active metabolite of methylphenidate prodrugs, emerged in illicit contexts before formal scheduling, highlighting the challenge of regulating designer drugs that may appear in uncontrolled or counterfeit formulations. While this scheduling decision does not directly impact standard methylphenidate prescribing for ADHD, it underscores the need for clinicians to remain vigilant about patients’ access to diverted or counterfeit stimulant medications, which may contain unexpected synthetic analogs. The regulatory approach also reflects broader uncertainty: we have limited human safety or efficacy data on many synthetic derivatives that appear in street supplies, making it difficult to counsel patients who may have encountered these substances. Clinicians should